FDA Requests Expanded Alcohol Warnings For Extended-Release Morphine Kadian
This article was originally published in The Pink Sheet Daily
Executive Summary
Alpharma's Kadian joins the list of extended-release opioid analgesics for which FDA has requested expanded label warnings regarding alcohol following the withdrawal of Palladone. Alpharma is planning to conduct in vivo bioequivalence studies with Kadian to assess the clinical implication of the in vitro data.
You may also be interested in...
Generic Moderate-Release Formulations Are More “Rugged” In Dose Dumping Tests By FDA
Quality-by-Design principles applied to alcohol-induced dose-dumping formulations suggested at Oct. 25-26 meeting of the Advisory Committee of Pharmaceutical Science.
Generic Moderate-Release Formulations Are More “Rugged” In Dose Dumping Tests By FDA
Quality-by-Design principles applied to alcohol-induced dose-dumping formulations suggested at Oct. 25-26 meeting of the Advisory Committee of Pharmaceutical Science.
Kadian Revenue Jump Offsets Alpharma's Loss Of Gabapentin Exclusivity
Increased sales and marketing efforts have driven the extended-release morphine's weekly prescription rates above 10,000.